CorePharma is a developer and manufacturer of high-quality targeted niche branded and generic pharmaceuticals across a variety of dosage forms and therapeutic categories. With headquarters in Middlesex NJ, CorePharma operates out of two state of the art manufacturing and packaging facilities with an annual capacity of over 1.5 billion dosage units.These facilities are both US FDA and DEA registered for CII-CV products.


Founded in 1998 by a group of industry entrepreneurs led by Dr. Vithal Dhaduk, MD., the company that was founded on family values and humble beginnings, grew rapidly in a short period of time to become a significant player in the generic drug industry.


CorePharma experienced tremendous growth along with an expanding product portfolio and a highly experienced and skilled team with a successful track record of delivering value. A majority equity interest in CorePharma was acquired by Roundtable Healthcare partners. From 2005 to 2015 Roundtable made significant investments in CorePharma to add new technologies, expansion for increased capacities and diversification into specialty niche generic and branded pharmaceuticals.


CorePharma was acquired by Impax Laboratories as a part of the acquisition of parent company Tower Holdings.


As of January 2018, CorePharma was acquired by a group of industry investors with an unwavering commitment to remain a trusted, reliable and preferred partner of choice for the development and manufacturing of high-quality generic and branded pharmaceuticals. Dr. Vithal Dhaduk, one of the original founders of CorePharma returned to the new ownership and management team as the President and Chairman of the Board alongside Arpit Patel who was appointed CEO and Board Member. Under the new ownership and management team the focus will be to create a quality centric sustainable business model that aligns with the company's long-term growth strategies.